AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26975053 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 928
Study 26975053 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Feeding Index (CFI)
Number of subjects: 928
Study 26975053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower length and weight
Number of subjects: 928
Study 26975053 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia prevalence in 6- to 12-month-olds
Number of subjects: 928
Study 26975053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin and sTfR levels
Number of subjects: 928
Study 25193991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucitanib (doses from 5 to 30 mg)
Number of subjects: 76
Study 21377114 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg BID
Number of subjects: 311
Study 21377114 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg BID
Number of subjects: 311
Study 21377114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 18339384 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified menotropin (HP-hMG, Menopur)
Number of subjects: 986
Study 18339384 — intervention group
Group type: COMPARATOR
Intervention: Recombinant follitropin alpha (rFSH, Gonal-F)
Number of subjects: 986
Study 17071297 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 67
Study 17071297 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrocautery tonsillectomy
Number of subjects: 67
Study 15071275 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 458
Study 15071275 — intervention group
Group type: COMPARATOR
Intervention: No ICD (control group)
Number of subjects: 458
Study 11205195 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (600 mg/m2/d at the first course, 700 mg/m2/d at the second and 800 mg/m2/d at the third course) and l‐folinic acid (150 mg/m2/d) or dl‐folinic acid (300 mg/m2/d) chronomodulated from 22:00 to 10.00 am with peak delivery rate at 4.00 for 5 days every 21 days
Number of subjects: 43
Study 11205195 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and folinic acid treatment
Number of subjects: 43
Study 8939037 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking about propositions implying positive or negative judgments
Number of subjects: 0
Study 8939037 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about the target's role (active agent vs. passive recipient role)
Number of subjects: 0
Study 1358243 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 1 mg
Number of subjects: 12
Study 1358243 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 2.5 mg
Number of subjects: 12
Study 1358243 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 5 mg
Number of subjects: 12
Study 4065773 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock-absorbing orthotic device
Number of subjects: 0
Study 4065773 — intervention group
Group type: COMPARATOR
Intervention: Nonorthotic group
Number of subjects: 0
Study 29617976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor (3 or 30 mg once daily, or 1, 3, 10 or 30 mg twice daily)
Number of subjects: 162
Study 29617976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 27739231 — intervention group
Group type: EXPERIMENTAL
Intervention: DW1029M (300 mg × 2T twice daily) with metformin (500 mg twice daily)
Number of subjects: 0
Study 27739231 — intervention group
Group type: EXPERIMENTAL
Intervention: DW1029M (300 mg × 2T twice daily) with losartan (50 mg once daily)
Number of subjects: 0
Study 27739231 — intervention group
Group type: EXPERIMENTAL
Intervention: DW1029M (300 mg × 2T twice daily) with linagliptin (5 mg once daily)
Number of subjects: 0
Study 26037731 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient initiation
Number of subjects: 1015
Study 26037731 — intervention group
Group type: COMPARATOR
Intervention: Outpatient initiation
Number of subjects: 1015
Study 24021824 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex deacon-tetra (N1,3-triazole,кN2) copper (II)
Number of subjects: 30
Study 24021824 — intervention group
Group type: COMPARATOR
Intervention: No relation (control group 4)
Number of subjects: 30
Study 21985286 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalloped group
Number of subjects: 93
Study 21985286 — intervention group
Group type: COMPARATOR
Intervention: Smooth group
Number of subjects: 93
Study 21985286 — intervention group
Group type: COMPARATOR
Intervention: Rough group
Number of subjects: 93
Study 19496782 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional treatment (mastectomy or breast conserving surgery with level I‐II axillary clearance) followed by radiation therapy to the whole breast and standard systemic therapy.
Number of subjects: 271
Study 19496782 — intervention group
Group type: COMPARATOR
Intervention: No locoregional treatment, standard systemic therapy given immediately after randomization.
Number of subjects: 271
Study 19496782 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional treatment (mastectomy or breast conserving surgery)
Number of subjects: 271
Study 19496782 — intervention group
Group type: COMPARATOR
Intervention: No locoregional treatment
Number of subjects: 271
Study 16779463 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper stamp checklist tool
Number of subjects: 104
Study 15547162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower in-treatment left ventricular mass index
Number of subjects: 941
Study 11122825 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy or chemoradiotherapy before surgery
Number of subjects: 0
Study 11122825 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy alone
Number of subjects: 0
Study 11122825 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 9113931 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic-enzyme supplements (mean dose 50,046 units of lipase per kg per day)
Number of subjects: 134
Study 9113931 — intervention group
Group type: COMPARATOR
Intervention: Control group (mean dose 18,985 units of lipase per kg per day)
Number of subjects: 134
Study 8478316 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg once daily
Number of subjects: 193
Study 8478316 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 250 mg four times daily
Number of subjects: 193
Study 3484503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial polysaccharide immune globulin (BPIG) administered intramuscularly at a dose of 0.5-0.6 ml/kg
Number of subjects: 54
Study 3484503 — intervention group
Group type: COMPARATOR
Intervention: Conventional immune serum globulin (ISG) administered intramuscularly at a dose of 0.5-0.6 ml/kg
Number of subjects: 54
Study 3484503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial polysaccharide immune globulin (BPIG)
Number of subjects: 54
Study 3484503 — intervention group
Group type: COMPARATOR
Intervention: Conventional immune serum globulin (ISG)
Number of subjects: 54
Study 29424437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0
Study 29424437 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 27399735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training (two 60‐min sessions each week for three months, plus 30 min self‐practice daily)
Number of subjects: 246
Study 27399735 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking (30 min every day)
Number of subjects: 246
Study 27399735 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 246
Study 24724439 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine intraperitoneal infiltration followed by 0.375% ropivacaine rectus sheath block
Number of subjects: 53
Study 24724439 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine intraperitoneal infiltration followed by 0.375% ropivacaine rectus sheath block
Number of subjects: 53
Study 21895979 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI plus bupropion
Number of subjects: 60
Study 21895979 — intervention group
Group type: COMPARATOR
Intervention: SSRI plus placebo
Number of subjects: 60
Study 20805113 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U/kg unfractionated heparin (UFH)
Number of subjects: 2505
Study 20805113 — intervention group
Group type: COMPARATOR
Intervention: 140 U/kg unfractionated heparin (UFH) (historical control)
Number of subjects: 2505
Study 18175742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-index (LGI) diet for 10 weeks
Number of subjects: 44
Study 18175742 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic-index (HGI) diet for 10 weeks
Number of subjects: 44
Study 17072885 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (200 mg) tablet 3 times a day plus conventional therapy
Number of subjects: 51
Study 17072885 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet plus conventional therapy
Number of subjects: 51
Study 13678228 — intervention group
Group type: EXPERIMENTAL
Intervention: Keishi-bukuryo-gan (KBG) 12 g daily for 4 weeks
Number of subjects: 30
Study 13678228 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline (PXF) 300 mg daily for 4 weeks
Number of subjects: 30
Study 10997480 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogens (CEE) daily
Number of subjects: 12
Study 10997480 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg conjugated equine estrogens (CEE) daily
Number of subjects: 12
Study 9361051 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized method for assessing chest radiographic results
Number of subjects: 805
Study 1391559 — intervention group
Group type: EXPERIMENTAL
Intervention: cotrimoxazole (29 patients)
Number of subjects: 90
Study 1391559 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxicillin‐clavulanic acid (32 patients)
Number of subjects: 90
Study 1391559 — intervention group
Group type: COMPARATOR
Intervention: placebo (29 patients)
Number of subjects: 90
Study 3902679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (1 g/kg)
Number of subjects: 10
Study 3902679 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (1 g/kg)
Number of subjects: 10
Study 30815856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mephedrone 50 mg
Number of subjects: 9
Study 30815856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mephedrone 100 mg
Number of subjects: 9
Study 30815856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mephedrone 150 mg
Number of subjects: 9
Study 30815856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mephedrone 200 mg
Number of subjects: 9
Study 29689594 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode + M-mode ultrasound
Number of subjects: 140
Study 29689594 — intervention group
Group type: COMPARATOR
Intervention: B-mode ultrasound alone
Number of subjects: 140
Study 29689594 — intervention group
Group type: EXPERIMENTAL
Intervention: M-mode ultrasound in providers with fewer than 250 scans
Number of subjects: 140
Study 29689594 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode + M-mode ultrasound in providers with more than 250 scans
Number of subjects: 140
Study 27101728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resection (SR)
Number of subjects: 69
Study 24843066 — intervention group
Group type: EXPERIMENTAL
Intervention: MD2Me intervention (2-month intensive Web-based and text-delivered disease management and skill-based intervention followed by a 6-month review period)
Number of subjects: 81
Study 24843066 — intervention group
Group type: EXPERIMENTAL
Intervention: MD2Me intervention
Number of subjects: 81
Study 24843066 — intervention group
Group type: COMPARATOR
Intervention: Control group (mailed materials on general health topics)
Number of subjects: 81
Study 22571951 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in depressive symptoms after myocardial infarction
Number of subjects: 767
Study 22571951 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed patients
Number of subjects: 767
Study 22571951 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 767
Study 20194251 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby videos (infant-directed DVD)
Number of subjects: 96
Study 20194251 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent report and observational measures of vocabulary acquisition
Number of subjects: 96
Study 20194251 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent report of general language development
Number of subjects: 96
Study 20194251 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent report of children's media use
Number of subjects: 96
Study 18580334 — intervention group
Group type: COMPARATOR
Intervention: Fixed iodine-dose protocol (80 mL Iopamidol-370, 20 seconds injection duration)
Number of subjects: 60
Study 18580334 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted iodine-dose protocol (1.0 mL/kg, 15 seconds injection duration)
Number of subjects: 60
Study 18580334 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted iodine-dose protocol
Number of subjects: 60
Study 18580334 — intervention group
Group type: COMPARATOR
Intervention: Fixed iodine-dose protocol
Number of subjects: 60
Study 16502725 — intervention group
Group type: EXPERIMENTAL
Intervention: OKM/A group: omeprazole 20 mg twice a day, clarithromycin 500 mg twice a day, metronidazole 500 mg or amoxicillin 1000 mg twice a day
Number of subjects: 65
Study 16502725 — intervention group
Group type: COMPARATOR
Intervention: OBTM group: omeprazole 20 mg twice a day, colloid bismuth subcitrate (de-nol) 120 mg four times a day, tetracycline 500 mg four times a day, metronidazole 500 mg twice or 250 mg four times a day
Number of subjects: 65
Study 12030739 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation
Number of subjects: 0
Study 12030739 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10346552 — intervention group
Group type: EXPERIMENTAL
Intervention: Short revisit intervals (1 to 2 months)
Number of subjects: 0
Study 10346552 — intervention group
Group type: EXPERIMENTAL
Intervention: Long revisit intervals (4 to 8 months)
Number of subjects: 0
Study 10346552 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment made immediately after the initial visit
Number of subjects: 0
Study 10346552 — intervention group
Group type: EXPERIMENTAL
Intervention: Calling back for an appointment according to the interval recommended by the provider
Number of subjects: 0
Study 10346552 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of clinic sessions for providers
Number of subjects: 0
Study 10346552 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced number of clinic sessions for providers
Number of subjects: 0
Study 8748321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (2.264 g)
Number of subjects: 7
Study 8748321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol solution
Number of subjects: 7
Study 8748321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol tablet
Number of subjects: 7
Study 8748321 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (control)
Number of subjects: 7
Study 1683334 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 40
Study 1683334 — intervention group
Group type: COMPARATOR
Intervention: Perazine
Number of subjects: 40
Study 6754511 — intervention group
Group type: EXPERIMENTAL
Intervention: Alclometasone dipropionate ointment (0.05%) applied twice daily for 3 weeks
Number of subjects: 66
Study 6754511 — intervention group
Group type: COMPARATOR
Intervention: Desonide ointment (0.05%) applied twice daily for 3 weeks
Number of subjects: 66
Study 31350585 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO-PCI
Number of subjects: 200
Study 31350585 — intervention group
Group type: COMPARATOR
Intervention: No-CTO PCI
Number of subjects: 200
Study 31345563 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for distal radius fracture
Number of subjects: 0
Study 31345563 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with severe pain and high school education or less
Number of subjects: 0
Study 31345563 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with less pain, more education, age 87 years or younger, and one or no comorbid conditions
Number of subjects: 0
Study 31345563 — intervention group
Group type: COMPARATOR
Intervention: Treatment type or radiographic measurements
Number of subjects: 0
Study 28406129 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm saline rinse (gargled twice daily)
Number of subjects: 100
Study 26691278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream QD
Number of subjects: 764
Study 26691278 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 0.75% cream BID
Number of subjects: 764
Study 24429255 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide whitening strips
Number of subjects: 170
Study 24429255 — intervention group
Group type: COMPARATOR
Intervention: Placebo strips without peroxide
Number of subjects: 170
Study 22253269 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral Position (0 degrees)
Number of subjects: 1320
Study 22253269 — intervention group
Group type: COMPARATOR
Intervention: Head Turned (45 degrees)
Number of subjects: 1320
Study 22253269 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1320
Study 19648304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic image-guided injection
Number of subjects: 148
Study 19648304 — intervention group
Group type: COMPARATOR
Intervention: Conventional palpation-guided injection
Number of subjects: 148
Study 17309916 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline infusion plus NAC (n=111)
Number of subjects: 326
Study 17309916 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate infusion plus NAC (n=108)
Number of subjects: 326
Study 17309916 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline plus ascorbic acid plus NAC (n=107)
Number of subjects: 326
Study 15381546 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal CO(2) laser resurfacing of photodamaged forearms
Number of subjects: 11
Study 12360766 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essential oil
Number of subjects: 5
Study 12360766 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile essential oil
Number of subjects: 5
Study 9843256 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amethocaine
Number of subjects: 0
Study 9843256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-conjunctival bupivacaine
Number of subjects: 0
Study 9843256 — intervention group
Group type: COMPARATOR
Intervention: Topical normal saline (placebo)
Number of subjects: 0
Study 7814312 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated communication
Number of subjects: 7
Study 2569995 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 56
Study 2569995 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 4 mg
Number of subjects: 56
Study 2569995 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 56
Study 2569995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 2569995 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments (Acrivastine and Terfenadine)
Number of subjects: 56
Study 22339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 84
Study 22339 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 84
Study 31758541 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin alfa 'conventional' dosing arm of the ESTHER‐1 trial
Number of subjects: 0
Study 31758541 — intervention group
Group type: COMPARATOR
Intervention: Clinic subpopulation using controlled ovarian stimulation with FSH
Number of subjects: 0
Study 30654990 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo with rationale (OPR+)
Number of subjects: 160
Study 30654990 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo without rationale (OPR-)
Number of subjects: 160
Study 30654990 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 160
Study 30654990 — intervention group
Group type: COMPARATOR
Intervention: Deceptive placebo (DP)
Number of subjects: 160
Study 28288299 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive dental images
Number of subjects: 60
Study 28288299 — intervention group
Group type: COMPARATOR
Intervention: Neutral cartoon images
Number of subjects: 60
Study 28288299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 25611762 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice therapy enhanced by MP4 support (4 sessions)
Number of subjects: 40
Study 25611762 — intervention group
Group type: COMPARATOR
Intervention: Voice therapy without MP4 support (4 sessions)
Number of subjects: 40
Study 24047450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral side-effect prevention training (SEPT)
Number of subjects: 184
Study 24047450 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 184
Study 24047450 — intervention group
Group type: COMPARATOR
Intervention: Manualized supportive therapy
Number of subjects: 184
Study 21651853 — intervention group
Group type: EXPERIMENTAL
Intervention: Achn inhibition group (transfected with psi‐Achn)
Number of subjects: 0
Study 21651853 — intervention group
Group type: EXPERIMENTAL
Intervention: Achn induction group (transfected with pcDNA‐Achn)
Number of subjects: 0
Study 21651853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotransfection group (cotransfected with psi‐CASK and pcDNA‐Achn)
Number of subjects: 0
Study 21651853 — intervention group
Group type: EXPERIMENTAL
Intervention: Achn transfection group (transfected with pcDNA‐Achn)
Number of subjects: 0
Study 19761535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous supplementation of trace elements (Se, Mn, Zn)
Number of subjects: 80
Study 19761535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17668563 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus cotrimoxazole
Number of subjects: 581
Study 17668563 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole alone
Number of subjects: 581